Meta-Analysis Finds Only Six Side Effects Causally Linked to Statins

A meta-analysis published in The Lancet in February 2026 found that only six commonly reported side effects are actually caused by statins, despite product labels listing more than 60 side effects associated with the drugs. The analysis, conducted by the Cholesterol Treatment Trialists' (CTT) Collaboration, pooled data from 19 double-blind randomized controlled trials comparing statins (atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin) versus placebo and included 123,940 participants with a median follow-up of 4.5 years.

Aside from muscle breakdown and new-onset diabetes, which had already been established in earlier analyses, only four additional side effects were statistically significant: abnormal liver transaminases, other liver function test abnormalities, urinary composition alteration, and edema, with rate ratios of 1.41, 1.26, 1.18, and 1.07, respectively. Analysis of four trials of more intensive versus less intensive statin regimens showed significant excesses for abnormal liver transaminases and other liver function test abnormalities, but no significant excess was found for urinary composition alteration or edema.

Over the years, statin users have reported a range of side effects, including erectile dysfunction, blurry vision, sleep disturbances, dizziness, and throat pain. The CTT's analysis found no clear evidence that statins were responsible for any of those symptoms.

All of the trials included in the analysis were industry-funded, and the data is only available to those within the CTT, which raises questions about the validity of the conclusions for some researchers. One cardiologist says she first requested access to the data nearly 15 years ago, after the CTT lead researcher presented earlier results at the 2012 European Society of Cardiology meeting.

A separate retrospective cohort study using data from the Korean National Health Insurance Service-Senior cohort examined 125,926 adults aged 60 years or older with fatty liver index of 30 or higher, followed from 2011 to 2019. During a median follow-up of 9 years, 3,445 liver-related events occurred over 1,054,343 person-years. Statin use was associated with a dose-dependent reduction in liver-related event risk. Compared with non-users, participants with 365 cumulative defined daily dose or higher had the lowest risk of total liver-related events (subdistribution hazard ratio, 0.69; 95% CI, 0.61–0.78), primary liver cancer (subdistribution hazard ratio, 0.63; 95% CI, 0.52–0.76), and liver cirrhosis (subdistribution hazard ratio, 0.66; 95% CI, 0.57–0.77). Moderate- to high-intensity statin conferred greater protection than low-intensity statin.

Statins are among the most prescribed drugs in the U.S. Many cardiologists view them as life-saving treatments that reduce the risk of heart attack and stroke by lowering cholesterol. While physicians and scientists mostly agree that statins are beneficial for those who have underlying risks of cardiovascular disease, their role as a preventative treatment in lower-risk individuals remains debated.